Highlights
- •Optimizing clinical trial conduct and data quality is essential for drug development.
- •Expert consensus recommendations to improve data quality discussed.
- •Key elements include: site selection and training, participant selection and training.
- •Key elements include: treatment adherence, data collection, and study monitoring.
Abstract
Perspective
Key Words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainReferences
- Impact of source data verification on data quality in clinical trials: An empirical post hoc analysis of three phase 3 randomized clinical trials.Br J Clin Pharmacol. 2015; 79: 660-668
- Medical histories may be unreliable in screening volunteers for clinical trials.Clin Pharmacol Ther. 1996; 60: 353-356
- The potential for central monitoring techniques to replace on-site monitoring: Findings from an international multi-centre clinical trial.Clin Trials. 2012; 9: 257-264
- Adherence to medications: Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.Annu Rev Pharmacol Toxicol. 2012; 52: 275-301
- Poor medication adherence in clinical trials: Consequences and solutions.Nat Rev Drug Discov. 2017; 16: 149-150
- Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.Clin Trials. 2017; 14: 584-596
- Can physical therapists deliver a pain coping skills program? An Examination of training processes and outcomes.Phys Ther. 2014; 94: 1443-1454
- Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory.Qual Life Res. 2014; 23: 897-906
Cai X, Gewandter JS, He H, Turk DC, Dworkin RH, McDermott MP: Estimands and missing data in clinical trials of chronic pain treatments: Advances in design and analysis. Pain 2020. Available at: https://journals.lww.com/pain/Abstract/9000/Estimands_and_missing_data_in_clinical_trials_of.98392.aspx. Accessed June 3, 2020
- Analysis of longitudinal trials with protocol deviation: A framework for relevant, accessible assumptions, and inference via multiple imputation.J Biopharm Stat. 2013; 23: 1352-1371
Code of Federal Regulations Title 21, part 11. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11. Accessed October 23, 2019
Code of Federal Regulations Title 21, part 312.50. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.50. Accessed October 23, 2019
CTSdatabase. Available at: http://ctsdatabase.com/. Accessed June 3, 2020
- Methods for the detection of carelessly invalid responses in survey data.J Exp Soc Psychol. 2016; 66: 4-19
- ESPACOMP Medication Adherence Reporting Guideline (EMERGE).Ann Intern Med. 2018; 169: 30-35
- Linear mixed-effects models for central statistical monitoring of multicenter clinical trials.Stat Med. 2014; 33: 5265-5279
- Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trials.Contemp Clin Trials Commun. 2017; 5: 67-71
- Concealment and fabrication by experienced research subjects.Clin Trials. 2013; 10: 935-948
DUPCHECK: Available at: https://www.dupcheck.org/. Accessed June 3, 2020
- Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.Pain. 2010; 149: 177-193
- Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.Pain. 2012; 153: 1148-1158
- Central and statistical data monitoring in the clinical randomisation of an antifibrinolytic in significant haemorrhage (CRASH-2) trial.Clinical Trials. 2014; 11: 336-343
- Sensible approaches for reducing clinical trial costs.Clin Trials. 2008; 5: 75-84
European Medicines Agency: Reflection paper on risk based quality management in clinical trials. 2013. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500155491.pdf. Accessed April 10, 2019
European Medicines Agency, Committee for Human Medicinal Products: ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2017. Available at:https://www.ema.europa.eu/documents/scientific-guideline/draft-ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical_en.pdf. Accessed April 10, 2019
- Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: An ACTTION study.Pain. 2014; 155: 1622-1631
- Structural mean effects of noncompliance: Estimating interaction with baseline prognosis and selection effects.J Am Stat Assoc. 2004; 99: 918-928
- Data fraud in clinical trials.Clin Investig (Lond). 2015; 5: 161-173
- Improving protocol design feasibility to drive drug development economics and performance.Int J Environ Res Public Health. 2014; 11: 5069-5080
- Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.Pain. 2014; 155: 1683-1695
- Navigating trials of personalized pain treatments: We're going to need a bigger boat.Pain. 2019; 160: 1235-1239
- Characterization and consequences of pain variability in individuals with fibromyalgia.Arthritis Rheum. 2005; 52: 3670-3674
- Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.Pain Med. 2013; 14: 1039-1047
- Clinical development success rates for investigational drugs.Nat Biotechnol. 2014; 32: 40-51
- Determinants of patient adherence: A review of systematic reviews.Front Pharmacol. 2013; 4: 91
- Application of methods for central statistical monitoring in clinical trials.Clin Trials. 2013; 10: 783-806
- Why do clinical trials fail? The problem of measurement error in clinical trials: Time to test new paradigms?.J Clin Psychopharmacol. 2007; 27: 1-5
- The high cost and questionable impact of 100% SDV.Center Watch Monthly. 2011; 19: 15-17
- Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs.Drug Discov Today. 2017; 22: 729-735
- Is bigger better for depression trials?.J Psychiatr Res. 2008; 42: 622-630
- Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.JAMA. 1988; 260: 641-651
- Tenofovir-based preexposure prophylaxis for HIV infection among African women.N Engl J Med. 2015; 372: 509-518
- Is it easier to find what you are looking for if you think you know what it looks like?.J Clin Psychopharmacol. 2007; 27: 121-125
- Using statistical techniques to detect fraud: A test case.Pharmaceutical Statistics. 2004; 3: 237-246
- The impact of clinical trial monitoring approaches on data integrity and cost-a review of current literature.Euro J Clin Pharm. 2016; 72: 399-412
- The hope and the hazards of using compliance data in randomized controlled trials.Stat Med. 1998; 17: 303-317
- Central statistical monitoring: Detecting fraud in clinical trials.Clinical Trials. 2013; 10: 225-235
- Key cost drivers of pharmaceutical clinical trials in the United States.Clin Trials. 2016; 13: 117-126
- Mitigating the effects of nonadherence in clinical trials.J Clin Pharmacol. 2016; 56: 1151-1164
- CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry.Innov Clin Neurosci. 2013; 10: 17-21
- A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy.Pain. 2014; 155: 1943-1954
- Survey Email Scheduling and Monitoring in eRCTs (SESAMe): A digital tool to improve data collection in randomized controlled clinical trials.J Med Internet Res. 2016; 18: e311
- Pain intensity rating training: Results from an exploratory study of the ACTTION PROTECCT system.Pain. 2016; 157: 1056-1064
- Risk-based source data verification approaches: Pros and cons.Regul Aff. 2010; 44: 745-756
- Statistical techniques to detect fraud and other data irregularities in clinical questionnaire data.Drug Inf Jour. 2002; 36: 115-125
- The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.JAMA. 1984; 251: 365-374
- A deeper look at pain variability and its relationship with the placebo response: results from a randomized, double-blind, placebo-controlled clinical trial of naproxen in osteoarthritis of the knee.Pain. 2019; 160: 1522-1528
- Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial.PLoS One. 2018; 13e0197844
- The value of source data verification in a cancer clinical trial.PLoS One. 2012; 7: e51623
U.S. Health and Human Services, Food and Drug Administration: Guidance for industry: Oversight of clinical investigations – A risk-based approach to monitoring. 2013. Available at: https://www.fda.gov/downloads/Drugs/Guidances/UCM269919.pdf. Accessed April 10, 2019
U.S. Health and Human Services, Food and Drug Administration: Guidance for industry: Electronic source data in clinical investigations. 2013. Available at:https://www.fda.gov/downloads/drugs/guidances/ucm328691.pdf. Accessed April 10, 2019
- Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: A consensus report from the Non-adherence Academic Research Consortium (NARC).Eur Heart J. 2018; 00: 1-16
- A statistical approach to central monitoring of data quality in clinical trials.Clin Trials. 2012; 9: 705-713
Verified Clinical Trials. Available at: http://www.verifiedclinicaltrials.com/
- Methods for measuring, enhancing, and accounting for medication adherence in clinical trials.Clin Pharmacol Ther. 2014; 95: 617-626
- Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence.Expert Rev Clin Pharmacol. 2014; 7: 633-644
- Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers.J Allergy Clin Immunol. 2009; 124 (436-44, 444e1-8)
Article info
Publication history
Footnotes
Financial Disclosure: The views expressed in this article are those of the authors and no official endorsement by the Food and Drug Administration (FDA) or the pharmaceutical and device companies that provided unrestricted grants to support the activities of the ACTTION public-private partnership should be inferred. Disclosures by individual authors are as follows:
Laurie Burke has received in the past 12 months compensation for consulting on clinical outcome assessment and labeling from AbbVie, Aclaris, Alnylam, Brickell, Dermtreat, Inflexxion, Ipsen, Ironshore, Jazz, Global Blood Therapeutics, and Zynerba.
In the past 5 years, Daniel Carr has received consulting fees from 1 startup company (no longer in business), for advice on potential acquisitions of nonopioid analgesics. To his knowledge, none were subsequently marketed. He has been an officer and member of professional associations that accept contributions from the pharmaceutical and medical device industries and use these and other revenues such as membership dues to cover officers’ expenses connected with their operations (eg, attending board or planning meetings). Dr Carr does not have investments, stock options or other holdings in such contributors. Other than ACTTION, these associations are the American Academy of Pain Medicine; the American Society of Anesthesiologists; the European Pain Federation; and the International Association for the Study of Pain (as a participant or representative at meetings or hearings). As a member of the National Institutes of Health (NIH) Interagency Pain Research Coordinating Committee/National Pain Strategy, he has received travel expenses from NIH to attend their meetings. Additionally, he has received or anticipates potentially receiving personal payments (including travel expenses) for occasional participation as an expert witness; service on an NIH-sponsored data safety monitoring board for a clinical trial; participation in a workshop convened by the National Academies of Science, Engineering and Medicine; and consultant fees from the Federal Trade Commission. He has received modest honoraria for participation in accredited medical education activities.
Philip Conaghan has done consultancies or speakers bureaus for AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, GlaxoSmithKline, Kolon TissueGene, Medivir, Novartis, Pfizer, Roche, Samumed and Stryker. P. Conaghan is supported in part by the UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre.
Eric Devine has grant and contract funding from NIAAA and NIDA as part of his salary support at Boston University. This includes reimbursed travel expenses to attend study kick-off meetings. Dr. Devine has received travel reimbursement from NIDA to participate as a speaker at an international conference. He has also received travel reimbursement from NIAAA to serve on a grant review committee. Dr. Devine has received teaching stipends from Adcare Educational Institute for conducting workshops on motivational interviewing and substance use treatment. He does not have individual investments, stocks, intellectual property in any healthcare-related industries.
Robert H. Dworkin has received in the past 36 months research grants and contracts from US Food and Drug Administration and US National Institutes of Health, and compensation for consulting on clinical trial methods from Abide, Adynxx, Analgesic Solutions, Aptinyx, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Concert, Dong-A, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Immune, Neumentum, NeuroBo, Novaremed, Novartis, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy, Relmada, Sandoz, Scilex, Semnur, Sollis, Teva, Theranexus, Trevena, and Vertex.
John T. Farrar, in the past 36 months has received: research grants and contracts from US Food and Drug Administration and US National Institutes of Health; compensation for consulting on clinical trial methods from Analgesic Solutions, Aptinyx, Biogen, Campbell Alliance, Daiichi Sankyo, DepoMed, Evadera, Jansen, Lilly, Novartis, and Pfizer; DSMB services from NIH-NIA and Cara Therapeutics; and services as associate editor from Wiley.
Jennifer Gewandter has received consulting income in the past 36 months from MundiPharma, Disarm Therapeutics, Asahi Kasei Pharma, and SK Life Science.
Ian Gilron has received support from Biogen, Adynxx, TARIS Biomedical, Astra-Zeneca, Pfizer, and Johnson & Johnson and has received grants from the Canadian Institutes of Health Research, Physicians’ Services Incorporated Foundation, and Queen's University.
Mark P. Jensen has received in the past 36 months research grants from the National Institutes of Health, the National Multiple Sclerosis Society, the Patient-Centered Outcomes Research Institute, The International Association for the Study of Pain, and the Washington State Spinal Injury Consortium. He has also received compensation for consultation from Goalistics.
Robert Kerns has received research funding from NIH, PCORI, Department of Veterans Affairs, Consortium of MS Centers and Honoraria from the American Academy of Pain Medicine (editorial board of Pain Medicine), American Pain Society (reviewer for APS-Pfizer grant program), American Care Management Association (Speaker), American College of Physicians (Speaker), Health Education Resource Organization (Speaker), and Duke University School of Medicine (Speaker). Amy A Kirkwood is funded by Cancer Research UK.
Michael P. McDermott has been supported in the past 36 months by research grants from NIH, FDA, NYSTEM, SMA Foundation, Cure SMA, and PTC Therapeutics. He has received compensation for consulting from Neuropore Therapies, Inc and Voyager Therapeutics. He has served on Data and Safety Monitoring Boards (DSMBs) for NIH, Novartis Pharmaceuticals Corporation, AstraZeneca, Eli Lilly and Company, aTyr Pharma, Inc, Catabasis Pharmaceuticals, Inc, Vaccinex, Inc, Cynapsus Therapeutics, and Voyager Therapeutics.
Kushang Patel has received in the past 36 months research grants and contracts from US Food and Drug Administration and US National Institutes of Health.
Andrew SC Rice reports the following conflicts of interest occurring in last 24 months 1) consultancy and advisory board work for Imperial College Consultants including remunerated work for: Pharmanovo, Galapagos, Toray, Quartet, Lateral, Novartis, Pharmaleads, Orion, Asahi Kasei & Theranexis; 2) owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued upon the acquisition of Spinifex by Novartis in July 2015 and from which future milestone payments may occur; 3) inventor on patents (a) Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771 (b) Okuse K. et al Methods of treating pain by inhibition of vgf activity EP13702262.0/ WO2013 110945.
Michael Rowbotham has received consulting income in the past 36 months from CODA, Amygdala Neurosciences, Nektar, Adynxx, Toray, and SiteOne Therapeutics.
Lee Simon has received consulting income from the following companies: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, JP Morgan, Regeneron, XTL, Inmedix, Eupraxia, Fidelity, Extera, Wyeth, Asahi, Sammuded, Metabolex, Shire, Anthera, Antares, Vical, Daiichi Sankyo, Flexion, AcelRx, Inotek, Gilead, Sandoz, Knopp, Abbott, Omeros, Jazz, Takeda, Teva, Zydus, Proprius, Alder, Cephalon, Purdue, EMDSerono, Alte, Talagen, Tigenix, Agenus, Forest, Genzyme, CaloSyn, pSivida, Horizon, Pozen, Eicos Sciences, Analgesic Solutions, Bayer, Kowa, Array, JRX Biopharm, Imprimis, Dara, Genco, Neos, Durect, Sanofi, Lilly, Idera, Medac, Remedy, Kiniksa.
Neil Singla is the Chief Executive Officer of Lotus Clinical Research, LLC and has received compensation for consulting from AcelRx Pharmaceuticals, AMAG Pharmaceuticals, Antibe Therapautics Inc, Aponia Laboratories, Inc, Arch Therapeutics, Astellas Pharma, Avenue Therapeutics, Biom¹Up, Bonti, Inc, Braeburn Pharmaceuticals, Inc, CerSci Therapeutics, Charleston Laboratories, Inc, Concentric Analgesics, Coronado Biosciences, Davol, a Bard Company, Durect Corporation, Grace Therapeutics, Inc, Grifols, Inc, Heron Therapeutics, Inc, INC Research/ Syneos Health, Innocoll Pharmaceuticals, Insys Therapeutics, Inc, iX Biopharma Ltd., KemPharm, Inc, KLSMC Stem Cells, Inc, Kowa Research Institute, Inc, Mallinckrodt Inc, a Covidien company, MedRx USA, Inc, Merck Sharp & Dohme Corp., Mira Pharma, Inc, Myoscience, Naurex, Inc, Neumentum, Inc, Novartis Consumer Health, Inc, Pacira Pharmaceuticals, Inc, Pfizer Inc, Recro Pharma, Inc, Regenacy Pharmaceuticals, Regeneron Pharmaceuticals, Serina Therapeutics, Shionogi Inc, Sollis Therapeutics, Teva Pharmaceuticals USA, TLC Biopharmaceuticals, Toyama Chemical Co., LTD, Trevena, Inc, Vertex Pharmaceuticals, Inc, Vizuri, Inc, Wex Pharmaceuticals.
Ajay D. Wasan has received in the past 36 months research grants and contracts from US National Institutes of Health, the Patient Centered Outcomes Research Institute, and Collegium Pharmaceuticals. He has received compensation for consulting from Pfizer and Analgesic Solutions.
All other authors report no conflicts.
